Pomalidomide-PEG6-butyl iodide is primarily utilized in the development of targeted cancer therapies, particularly in the field of proteolysis-targeting chimeras (PROTACs). Its structure, combining pomalidomide with a PEG6 linker and a butyl iodide group, allows it to serve as a key component in designing molecules that can selectively degrade disease-causing proteins.

The compound is often employed in research to create bifunctional molecules that link a target protein to an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of the protein. This approach is especially relevant in treating cancers driven by specific proteins that are otherwise difficult to target with traditional small-molecule inhibitors.

Additionally, the PEG6 linker enhances solubility and bioavailability, making the compound more effective in biological systems. Its application extends to studying protein-protein interactions and developing novel therapeutic strategies for diseases beyond cancer, such as neurodegenerative disorders and autoimmune conditions.